Q1 FY27 results: Revenue up 25%, PAT up 31%; Rs 32 per share dividend

Revenue Growth 20pctPat Growth 25pctEmphasis Of MatterResults View source PDF Explain this filing

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹3409.00

prior close

₹3422.10

announcement price

In-mkt

timing

Nifty Midcap 150market-0.4%+1.4% vs market

Pharmaceuticals peers, median of 162sector-0.8%+1.8% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Midcap 150 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.6

10m

+2.0

15m

+0.6

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0-0.4+1.4-0.8+1.8

Next day

+1.8+0.1+1.7-0.5+2.3

+3.0+1.3+1.7+0.2+2.8

+3.0+1.0+2.0+0.1+2.9

+0.9+1.2-0.3+0.5+0.5

+1.0+0.8+0.2+0.4+0.6

+2.9+1.5+1.4+1.4+1.5

15d

+8.2+1.1+7.1+0.3+7.9

+5.6+1.8+3.8+1.6+4.0

+5.4-5.4+10.8+2.7+2.7

+1.6pendingpending-3.1+4.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 results. Consolidated revenue at Rs 1,626 cr, up 25% YoY. PAT at Rs 334 cr, up 31% YoY. Adjusted EBITDA at Rs 454 cr with 28 percent margin. India branded grew 24 percent, US generics up 57 percent, Africa up 30 percent, while Asia fell 16 percent on war impact. Interim dividend of Rs 32 per share, total payout around Rs 400 cr. Record date 5 Aug 2026.

Likely market impact

Strong Q1 with broad growth in India, US, and Africa plus meaningful dividend signals confidence. Watch Asia weakness and pending tax matter.